-
Mashup Score: 92Oral Muvalaplin for Lowering of Lipoprotein(a) - 2 day(s) ago
This randomized clinical trial assesses the effect of muvalaplin on lipoprotein(a) concentrations in patients with high baseline lipoprotein(a) levels and cardiovascular risk factors.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 19Zerlasiran鈥擜 Small-Interfering RNA Targeting Lipoprotein(a) - 4 day(s) ago
This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentration.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet-
#AHA24 #CVPrev #LBCT 馃珋178 patients with ASCVD: siRNA Zerlasiran trial to assess safety & Lp(a) lowering 馃珋dosing below Zerlasiran 馃啔 Placebo 馃珋猡碉笍 Lp(a) by >80% during 36 weeks of tx, no safety concerns @AHAScience @JAMA_current https://t.co/ydDGslWuOa https://t.co/AYDPmwuZXS
-
-
Mashup Score: 0
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet-
馃搸 @NEJM #AHA24 https://t.co/4vbqJOaHyz https://t.co/5Y7zboenYB
-
-
Mashup Score: 19Zerlasiran鈥擜 Small-Interfering RNA Targeting Lipoprotein(a) - 5 day(s) ago
This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentration.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet-
#AHA24 #CVPrev #LBCT 馃珋178 patients with ASCVD: siRNA Zerlasiran trial to assess safety & Lp(a) lowering 馃珋dosing below Zerlasiran 馃啔 Placebo 馃珋猡碉笍 Lp(a) by >80% during 36 weeks of tx, no safety concerns @AHAScience @JAMA_current https://t.co/ydDGslWuOa https://t.co/AYDPmwuZXS
-
-
Mashup Score: 89Oral Muvalaplin for Lowering of Lipoprotein(a) - 6 day(s) ago
This randomized clinical trial assesses the effect of muvalaplin on lipoprotein(a) concentrations in patients with high baseline lipoprotein(a) levels and cardiovascular risk factors.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet-
#AHA24 馃珋oral, small molecule Muvalaplin inhibits Lp(a) formation 馃珋233 pt with 猡达笍 Lp(a) >175 w/ ASCVD, DM, FH, mean age 66, 33%馃拑馃徎 馃珋 Muvalaplin was well tolerated & produced dose dependent 猡碉笍 Lp(a) in patients at 猡达笍risk of CV events @JAMA_current 馃搸 https://t.co/tHtdj9rYYm
-
-
Mashup Score: 89Oral Muvalaplin for Lowering of Lipoprotein(a) - 6 day(s) ago
This randomized clinical trial assesses the effect of muvalaplin on lipoprotein(a) concentrations in patients with high baseline lipoprotein(a) levels and cardiovascular risk factors.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet-
#AHA24 馃珋oral, small molecule Muvalaplin inhibits Lp(a) formation 馃珋233 pt with 猡达笍 Lp(a) >175 w/ ASCVD, DM, FH, mean age 66, 33%馃拑馃徎 馃珋 Muvalaplin was well tolerated & produced dose dependent 猡碉笍 Lp(a) in patients at 猡达笍risk of CV events @JAMA_current 馃搸 https://t.co/tHtdj9rYYm
-
-
Mashup Score: 19Zerlasiran鈥擜 Small-Interfering RNA Targeting Lipoprotein(a) - 6 day(s) ago
This phase 2 randomized clinical trial evaluates the optimal dose, dosing interval, and safety of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), to treat patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentration.
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet-
#AHA24 #CVPrev #LBCT 馃珋178 patients with ASCVD: siRNA Zerlasiran trial to assess safety & Lp(a) lowering 馃珋dosing below Zerlasiran 馃啔 Placebo 馃珋猡碉笍 Lp(a) by >80% during 36 weeks of tx, no safety concerns @AHAScience @JAMA_current https://t.co/ydDGslWuOa https://t.co/AYDPmwuZXS
-
-
Mashup Score: 0
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet-
馃搸 @NEJM #AHA24 https://t.co/4vbqJOaHyz https://t.co/5Y7zboenYB
-
-
Mashup Score: 14Electronic Nudges and Influenza Vaccination After AMI - 7 day(s) ago
This randomized clinical trial investigates if behavioral nudges delivered electronically that highlight the cardiovascular benefits of vaccination improve influenza vaccine uptake in patients with acute myocardial infarction (AMI).
Source: jamanetwork.comCategories: General Medicine News, Expert PicksTweet-
馃拤 among those with #AMI message was most effective in vaccine hesitant & younger pts with AMI 馃拤 Patients with AMI: greater uptake when letter explained CV recommendation 馃拤more impactful with recent events 馃搸 https://t.co/UVrnF8wMrS @JAMACardio #AHA24 https://t.co/viePnxuX4y
-
-
Mashup Score: 0
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor…
Source: www.nejm.orgCategories: General Medicine News, Expert PicksTweet-
馃搸 @NEJM #AHA24 https://t.co/4vbqJOaHyz https://t.co/5Y7zboenYB
-
#AHA24 馃珋oral, small molecule Muvalaplin inhibits Lp(a) formation 馃珋233 pt with 猡达笍 Lp(a) >175 w/ ASCVD, DM, FH, mean age 66, 33%馃拑馃徎 馃珋 Muvalaplin was well tolerated & produced dose dependent 猡碉笍 Lp(a) in patients at 猡达笍risk of CV events @JAMA_current 馃搸 https://t.co/tHtdj9rYYm